학술논문
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy
Document Type
Article
Author
Source
In Annals of Oncology March 2018 29(3):737-743
Subject
Language
ISSN
0923-7534